Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab

BACKGROUND: Patients on B-cell-depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or suffering from a more severe prognosis. Indeed, available data on pre-exposure prophylaxis with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciascia, Savino, Rilat, Maria Letizia Antonietta, Fenoglio, Roberta, Foddai, Silvia Grazietta, Radin, Massimo, Cecchi, Irene, Cinnirella, Giacoma, Crosasso, Paola, Guidetti, Maria Gabriella, Barinotti, Alice, Baldovino, Simone, Menegatti, Elisa, Roccatello, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469100/
https://www.ncbi.nlm.nih.gov/pubmed/37664578
http://dx.doi.org/10.1093/ckj/sfad111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469100/
https://www.ncbi.nlm.nih.gov/pubmed/37664578
http://dx.doi.org/10.1093/ckj/sfad111

Ejemplares similares